Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Frederick E. Pierce, II as a Director

On September 9, 2022, the Board of Directors of Inovation1 Biotech Inc. has appointed Frederick E. Pierce, II as a member of the Board. A copy of the press release is included as Exhibit 99.1 to this Current Report.

Mr. Pierce, age 61, is the Chief Executive Officer and Co-founder of Decoy Therapeutics, Inc. founded in 2020. Decoy has corporate offices in Cambridge, MA and a lab at JLABs New York City, supported by Johnson and Johnson and BARDA's BlueKnight™ Program, grants from one of the world's most well-known public health foundations from Seattle, WA., institutional healthcare investors, Federal and State Government agencies. Mr. Pierce is also an Advisor to the Canadian Consulate of Boston/Cambridge's Healthcare and Technology Accelerator and a Board member of the Canadian Entrepreneurs of New England, where he is Chairman of the Life Sciences Leadership Council.

From 2017 - 2020, Mr. Pierce served as a Senior Advisor for Bionest Partners based in Paris and New York. The firm provides leading global pharmaceutical and biotech companies strategic advice on matters including, market access, licensing valuation and strategy, reimbursement and drug pricing, as well as venture capital diligence support services.

Mr. Pierce is a serial biotech entrepreneur with over 20 years of increasing senior leadership and operating experience building successful biotech companies. This included senior management and turn-around advisory roles at several public biotech start-ups that listed on the NASDAQ, New York Stock and Toronto Stock Exchange. At Javelin Pharmaceuticals (NYSE:JAV) he was VP of Investor Relations, while the Company raised $183M, went public, got a non-opioid pain drug Dyloject™ approved globally and was bought out by Hospira, now Pfizer. After Javelin, he was recruited by SemBioSys Genetics (TSE: SBS) as President of US and International Operations, to assist in a turnaround of the Company's biotech business. He further served as a strategic advisor to Canada based Cangene (TSX:CNJ), sold to Emergent BioSolutions for $222M. He also was an Advisor to Spring Bank Pharmaceuticals management and BOD during and after its IPO on NASDAQ.

Mr. Pierce was a VP of Business Development and Investor Relations and became CEO Glycogenesys (NASDAQ: GLGS sold to Lajolla Pharmaceuticals), A VP of Finance and Investors relations for (NASDAQ: SAFS) SafeScience, predecessor Company of GlycoGenesys. During Mr. Pierce's time at SafeScience, the Company up-listed to NASDAQ at a $25M valuation, raised $85M in equity capital and achieved a peak market capitalization of over $550M. He led the successful effort to partner its lead drug GCS-100 to Elan Pharmaceuticals in a strategic joint venture that included $35M in upfronts, milestones and royalty payments.

Mr. Pierce has a proven track record in attracting capital, forging transformative strategic global alliances and working with investors to create successful outcomes of public and private healthcare companies.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



  99.1       Press Release dated September 15, 2022.
104        Cover Page Interactive Data File (embedded within the Inline XBRL
           Document)





2

© Edgar Online, source Glimpses